In particular, obesity drugmakers aren’t likely to experience any disruption under the Trump administration, according to Jeff Jonas, a portfolio manager at Gabelli Funds. Seniors should continue to get access to GLP-1s like Ozempic, and Medicare is likely to cover the drugs to treat different co-morbidities once the medications get the go-ahead beyond their existing approvals for type 2 diabetes and sleep apnea.
